ACTIVITIES OF D0870, A NOVEL TRIAZOLE, AGAINST CANDIDA-LUSITANIAE ANDTRICHOSPORON-BEIGELII IN EXPERIMENTAL MURINE INFECTIONS

Candida lusitaniae and Trichosporon beigelii may cause life-threatenin g infections in the immunocompromised host and may be resistant to amp hotericin B. We assessed the activities of a new triazole, D0870, agai nst one T. beigelii and four C. lusitaniae strains, in comparison with those of fluconazole and amphotericin B. Immunosuppressed CF1 mice, i ntravenously infected with each fungal strain, received 3 days of ther apy with oral D0870 (5 or 25 mg/kg of body weight daily), fluconazole (5 to 50 mg/kg daily), or parenteral amphotericin B (1 or 2 mg/kg dail y). Survival was significantly prolonged and kidney fungus titers were reduced in mice treated with D0870 compared with untreated mice (P le ss than or equal to 0.05). Treatment with D0870 was significantly more effective than that with amphotericin B or fluconazole in animals inf ected with two of the C. lusitaniae strains and equally effective for the remaining two C. lusitaniae strains and the T. beigelii strain. Fl uconazole and amphotericin B failed to improve the survival of mice in fected with one and two C. lusitaniae strains, respectively. D0870 was active against all the organisms tested, including those resistant to fluconazole and amphotericin B.